C Diff Drug Development

Clostridioides difficile infection (CDI) is a leading cause of antibiotic-associated diarrhoea. Adhesion of this Gram-positive pathogen to the intestinal epithelium is a crucial step in CDI, with recurrence and relapse of disease dependent on epithelial interaction of its endospores. Close pr …

.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrialsBelieve precision #antibiotic spares #microbiome from damagehttps://t.co/ED6zpkmEqQ#Cdifficile #InfectiousDiseases pic.twitter.com/oUc6TuNkn7— DDNews Online (@DDNewsOnline) December 20, 2021

Recursion Pharma (RXRX) is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities.

Bacterial adhesion is the first stage of colonisation and biofilm formation by C. difficile. Cell wall proteins (Cwp) 84 and 66 play crucial roles in the pathophysiology of C. difficile and may affect bacterial adhesion. Sialylated human milk oligosaccharides (HMOs) have potential to inhibit bacteri …

Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutrali …

Infectious Disease Society of America and Society for Healthcare Epidemiology of America make 3 new treatment recommendations for adults.

Seres Therapeutics, Inc. today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Lumen also announces successful Cohort 1 results in Phase 1 clinical trial.

Chemical engineers created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal diseases. The human gut is home to thousands of species of bacteria, and some of those bacteria have the potential to treat a variety of gastrointestinal diseases. Some sp

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.

Jessica R. Allegretti, MD, MPH, spoke with Healio about a study demonstrating the efficacy of SER-109 in preventing recurrent Clostridioides difficile infection, including in patients using acid-suppressing medications.The data, presented at the ACG Annual Meeting, showed that SER-109 (Seres Therapeutics), an oral investigational microbiome therapeutic, reduced recurrent C. difficile infection

In this video, Jessica R. Allegretti, MD, MPH, discussed findings from the PRISM3 trial evaluating an investigational therapeutic for the prevention of recurrent Clostridioides difficile infection.Allegretti, director of the fecal microbiota center at Brigham and Women’s Hospital, presented the trial findings at the ACG Annual Meeting.

In this video, Jessica R. Allegretti, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting that provided an overview of microbiome therapeutics  currently under investigation for Clostridioides difficile infection.During his presentation, Sahil Khanna, MBBS, MS, professor of medicine at the Mayo Clinic in Rochester, Minnesota, showed data on RBX2660 (Rebiotix Inc.),

Chemical engineers have developed a protective coating that helps anaerobic microbes survive the manufacturing process, making it potentially easier to use them to treat gastrointestinal disease.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Acurx Pharmaceuticals Inc. earned a 12-month price target of $12 from analysts at Maxim Group. Coverage was initiated with a BUY rating, and its price target covering the next twelve months. Shares... | December 6, 2021

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).

Bacthera, the joint venture between Chr. Hansen and Lonza, is to team up with Seres Therapeutics to manufacture Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).

Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions, informed by a systems biology high-throughput interrogation of multidimensional omics and whole structural data, coupled wi …

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

Within the local setting of our study, CDI within 12 months post-LT is of low severity, associated with pre-LT antibiotic exposure and longer hospital stay but no survival impact after LT. Rifaximin use pre-LT reduced the risk of CDI post-LT. This article is protected by copyright. All rights reserv …